NovaBay Pharmaceuticals, Inc. (formerly known as NovaCal Pharmaceuticals, Inc.) to Present at the 2010 Biotechnology Industry Organization (BIO) CEO & Investor Conference

EMERYVILLE, CA--(Marketwire - February 04, 2010) - NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY), a clinical stage biopharmaceutical company developing first-in-class, anti-infective compounds in the treatment and prevention of antibiotic-resistant infections, today announced that Ron Najafi, Ph.D., Chairman and Chief Executive Officer, will deliver a corporate presentation at the 12th Annual BIO CEO & Investor Conference on Tuesday, Feb. 9 in New York City.

Dr. Najafi's presentation will take place at 2:30 p.m. ET in the Duke of Windsor room at the Waldorf Astoria. His presentation will provide a corporate overview and highlight NovaBay's clinical progress in its internal programs, as well as in its partnered programs with Alcon (NYSE: ACL) and Galderma.

An audio of the presentation will be available on NovaBay's homepage at www.novabaypharma.com.

About NovaBay

NovaBay Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing its proprietary and patented Aganocide® compounds, which are novel, synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white blood cells. NovaBay's Aganocides are being developed to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has internal development programs aimed at addressing hospital and respiratory infections. The company has a license and research collaboration agreement with Alcon, Inc. for use of its Aganocide compounds to treat eye, ear and sinus infections as well as for contact lens care. NovaBay has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo and other dermatological indications. For more information on NovaBay, visit: www.novabaypharma.com.